http://orcid.org/0000-0002-1725-9866
Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Inês Alves, Marta Gromicho, Miguel Oliveira Santos, Susana Pinto, Ana Pronto-Laborinho, Michael Swash & Mamede de Carvalho. (2023) Demographic changes in a large motor neuron disease cohort in Portugal: a 27 year experience. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24:7-8, pages 614-624.
Read now
Read now
Elisabet Romero-Gangonells, M. Núria Virgili-Casas, Mònica Povedano & Maria A Barceló. (2023) Clinical and demographical characteristics in a cohort of MND patients treated with riluzole. Differences between tablets and oral suspension. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 24:5-6, pages 369-382.
Read now
Read now
Betts Peters, Kerth O’Brien & Melanie Fried-Oken. (2022) A recent survey of augmentative and alternative communication use and service delivery experiences of people with amyotrophic lateral sclerosis in the United States. Disability and Rehabilitation: Assistive Technology 0:0, pages 1-14.
Read now
Read now
Todd M. Bear, Angela M. Malek, Abigail Foulds, Judith Rager, Sarah E. Deperrior, John E. Vena, Theodore C. Larson, Paul Mehta, D. Kevin Horton & Evelyn O. Talbott. (2021) Recruitment of population-based controls for ALS cases from the National ALS Registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22:5-6, pages 395-400.
Read now
Read now
Jinsy A. Andrews, Carlayne E. Jackson, Terry D. Heiman-Patterson, Paolo Bettica, Benjamin Rix Brooks & Erik P. Pioro. (2020) Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:7-8, pages 509-518.
Read now
Read now
Angeline S. Andrew, Katie M. O’Brien, Brian P. Jackson, Dale P. Sandler, Wendy E. Kaye, Laurie Wagner, Elijah W. Stommel, D. Kevin Horton, Paul Mehta & Clarice R. Weinberg. (2020) Keratinous biomarker of mercury exposure associated with amyotrophic lateral sclerosis risk in a nationwide U.S. study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21:5-6, pages 420-427.
Read now
Read now
Articles from other publishers (22)
Christina Martin Schaff, Jerome E. Kurent, Sherry Kolodziejczak, Michelle Milic, Laura A. Foster & Ambereen K. Mehta. (2023) Neuroprognostication for Patients with Amyotrophic Lateral Sclerosis: An Updated, Evidence-Based Review. Seminars in Neurology 43:05, pages 776-790.
Crossref
Crossref
Anas Zakarya Nourelden, Ibrahim Kamal, Abdulrahman Ibrahim Hagrass, Abdelrahman G. Tawfik, Mahmoud M. Elhady, Ahmed Hashem Fathallah, Mona Muhe Eldeen Eshag & Mohamed Sayed Zaazouee. (2023) Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurological Sciences.
Crossref
Crossref
Cara Donohue, Lauren Tabor Gray, Amber Anderson, Lauren DiBiase, James P. Wymer & Emily K. Plowman. (2023) Profiles of Dysarthria and Dysphagia in Individuals With Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research 66:1, pages 154-162.
Crossref
Crossref
Aya Murakami, Shunsuke Koga, Hiroaki Sekiya, Björn Oskarsson, Kevin Boylan, Leonard Petrucelli, Keith A. Josephs & Dennis W. Dickson. (2022) Old age amyotrophic lateral sclerosis and limbic TDP‐43 pathology. Brain Pathology 32:6.
Crossref
Crossref
Yuko Kobayakawa, Koji Todaka, Yu Hashimoto, Senri Ko, Wataru Shiraishi, Junji Kishimoto, Jun-ichi Kira, Ryo Yamasaki & Noriko Isobe. (2022) A novel quantitative indicator for disease progression rate in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 442, pages 120389.
Crossref
Crossref
Lindsay Rechtman, Stephan Brenner, Marcienne Wright, Maggie Ritsick, Farhana Rahman, Moon Han, Jaime Raymond, Theodore Larson, D. Kevin Horton & Paul Mehta. (2022) Impact of the National Amyotrophic Lateral Sclerosis Registry: Analysis of Registry‐funded Research. Annals of Clinical and Translational Neurology 9:11, pages 1692-1701.
Crossref
Crossref
Benjamin Rix Brooks, James D. Berry, Malgorzata Ciepielewska, Ying Liu, Gustavo Suarez Zambrano, Jeffrey Zhang & Melissa Hagan. (2022) Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis. eClinicalMedicine 52, pages 101590.
Crossref
Crossref
Angela Genge, Benjamin Rix Brooks, Björn Oskarsson, Alexander Kalin, Ming Ji, Stephen Apple & Laura Bower. (2022) Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch. Drugs in R&D 22:3, pages 205-211.
Crossref
Crossref
Hiroshi Hori, Takahiko Fukuchi & Hitoshi Sugawara. (2022) Abdominal Muscle Fasciculations and Amyotrophic Lateral Sclerosis Diagnosis in a Patient Unable to Perform Sit-Ups. Cureus.
Crossref
Crossref
Zhengqing He, Bo Sun, Feng Feng, Jiongming Bai, Haoran Wang, Hongfen Wang, Fei Yang, Fang Cui & Xusheng Huang. (2021) Time of symptoms beyond the bulbar region predicts survival in bulbar onset amyotrophic lateral sclerosis. Neurological Sciences 43:3, pages 1817-1822.
Crossref
Crossref
Mai Yamakawa, Sally Dwyer, Xing Song & Jeffrey Statland. (2021)
Demographics, clinical characteristics, and prognostic factors of amyotrophic lateral sclerosis in
M
idwest
. Muscle & Nerve 65:2, pages 217-224.
Crossref
Crossref
Maria Puopolo, Ilaria Bacigalupo, Paola Piscopo, Eleonora Lacorte, Alessandra Di Pucchio, Marialaura Santarelli, Maurizio Inghilleri, Antonio Petrucci, Mario Sabatelli & Nicola Vanacore. (2021) Prevalence of amyotrophic lateral sclerosis in Latium region, Italy. Brain and Behavior 11:12.
Crossref
Crossref
Suzanne F. Cook, Thomas Rhodes, Courtney Schlusser, Steve Han, Chao Chen, Neta Zach, Venkatesha Murthy & Shreya Davé. (2021) A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis. Frontiers in Neurology 12.
Crossref
Crossref
Onur Akan & Leyla Baysal-Kirac. (2020) Amyotrophic lateral sclerosis with coexisting cancer: a single-center study. Acta Neurologica Belgica 121:5, pages 1123-1130.
Crossref
Crossref
Benjamin Rix Brooks & Jerome E. Kurent. 2021. Public Policy in ALS/MND Care. Public Policy in ALS/MND Care
301
326
.
Ashley Myer, Cynthia Pathmathasan & Eliot N. Mostow. 2021. Dermatoethics. Dermatoethics
401
411
.
Angeline S. Andrew, Walter G. Bradley, Daniel Peipert, Tanya Butt, Kwadwo Amoako, Erik P. Pioro, Rup Tandan, John Novak, Adam Quick, K. Doug Pugar, Komal Sawlani, Bashar Katirji, Todd A. Hayes, Pamela Cazzolli, Jiang Gui, Paul Mehta, D. Kevin Horton & Elijah W. Stommel. (2020) Risk factors for amyotrophic lateral sclerosis: A regional United States case‐control study. Muscle & Nerve 63:1, pages 52-59.
Crossref
Crossref
Ji He, Jia yu Fu, Lu Chen, Jing He, Jingxia Dang, Zhangyu Zou, Sha Ma, Nan Li & Dongsheng Fan. (2020) Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol. BMJ Open 10:12, pages e042603.
Crossref
Crossref
Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef & Stephen Tomlinson. (2020) Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?. Frontiers in Immunology 11.
Crossref
Crossref
Matthew J. Fogarty. (2020) Needles in straw-stacks on camel’s backs: Globalized versus specific loci of dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology 131:4, pages 940-941.
Crossref
Crossref
Azim Malekshahi, Ujwal Chaudhary, Andres Jaramillo-Gonzalez, Alberto Lucas Luna, Aygul Rana, Alessandro Tonin, Niels Birbaumer & Steffen Gais. (2019) Sleep in the completely locked-in state (CLIS) in amyotrophic lateral sclerosis. Sleep 42:12.
Crossref
Crossref
Helder Vieira, Nelson Costa, Tomás Sousa, Sara Reis & Luis Coelho. (2019) Voice-Based Classification of Amyotrophic Lateral Sclerosis: Where Are We and Where Are We Going? A Systematic Review. Neurodegenerative Diseases 19:5-6, pages 163-170.
Crossref
Crossref